Turner White CommunicationsAbout TWCSubscribeContact TWCHomeSearch
Hospital PhysicianJCOMSMPBRMsCart
Current Contents
Past Issue Archives
Interactive:
Self-Assessment Questions
Review of
Clinical Signs
Clinical Review
Quiz
Pediatric Rounds
Resident Grand Rounds
Article Archives
Case Reports
Clinical Practice
Exams
Pediatric Rounds
Resident Grand Rounds
Review of
Clinical Signs

Guide to Reading
Hospital Physician
Editorial Board
Information for Authors

Reprints, Permissions, & Copyright
Site Map


Self-Assessment Questions

Infectious Diseases

Hepatitis C: Review Questions

George J. Alangaden, MD

Dr. Alangaden is an Associate Professor of Internal Medicine, Division of Infectious Diseases, Wayne State University School of Medicine, Detroit, MI.


Choose the single best answer for each question.

1. Which of the following factors is associated with a slower progression of hepatitis C virus (HCV) infection to chronic liver disease?
  1. Alcohol use
  2. Female gender
  3. HCV genotype 2
  4. Older age at infection
Click here to compare your answer.


2. On which of the following criteria should selection of patients for treatment of chronic hepatitis C infection be based?

  1. HCV genotype
  2. Liver biopsy results
  3. Serum HCV RNA levels
  4. Serum transaminase levels
Click here to compare your answer.


3. A 44-year-old man with end-stage renal disease is evaluated for therapy of chronic hepatitis C infection (genotype 2). He has strictly abstained from alcohol for the past 6 months. His serum alanine aminotransferase level is 250 U/L, and his HCV RNA level is detectable. Results of a liver biopsy reveal evidence of fibrosis and severe necrosis and inflammation. Which of the following is the best therapeutic option for this patient?

  1. Administration of interferon and ribavirin
  2. Administration of pegylated interferon alfa
  3. Administration of pegylated interferon and ribavirin
  4. No therapy
Click here to compare your answer.


4. A 52-year-old man with chronic hepatitis C infection (genotype 1) and moderate hepatic fibrosis and inflammation on liver biopsy is treated with pegylated interferon and ribavirin. After 12 weeks of therapy, his HCV RNA level has declined by 1 log. Which of the following is the most appropriate next step in his treatment
  1. Continue treatment for a total of 24 weeks
  2. Continue treatment for a total of 48 weeks
  3. Discontinue treatment
  4. Repeat liver biopsy and assess the need for further therapy
Click here to compare your answer.
 

Self-Assessment Questions Main Page Top

Hospital Physician     JCOM     Seminars in Medical Practice
Hospital Physician Board Review Manuals
About TWC    Subscribe    Contact TWC    Home    Search   Site Map

Copyright © 2009, Turner White Communications
Updated 1/04/08 • kkj